1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,200 | 1,240 | 27.08. | |
| 1,200 | 1,260 | 27.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.08. | NanoViricides: A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials | 370 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / August 18, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development... ► Artikel lesen | |
| 30.07. | Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides | 614 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen | |
| 23.07. | NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value | 691 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / July 23, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the development... ► Artikel lesen | |
| 21.07. | Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides | 758 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 21, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the development of... ► Artikel lesen | |
| NANOVIRICIDES Aktie jetzt für 0€ handeln | |||||
| 16.07. | WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides | 713 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / July 16, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development... ► Artikel lesen | |
| 14.07. | Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides | 827 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen | |
| 01.07. | NanoViricides: There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate | 589 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 1, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen | |
| 18.06. | With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan | 596 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / June 18, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.: NNVC ) (the "Company"), asserts that with new rising variants of COVID and Bird Flu, the... ► Artikel lesen | |
| 04.06. | NanoViricides Measles Drug Development Animal Study is Imminent | 663 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / June 4, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen | |
| 28.05. | NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025 | 977 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 28, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus... ► Artikel lesen | |
| 22.05. | The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan | 844 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 22, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.:NNVC ) (the "Company"), comments on the new COVID Vaccine policy adopted by the US FDA.The... ► Artikel lesen | |
| 16.05. | NanoViricides GAAP EPS of -$0.14 | 7 | Seeking Alpha | ||
| 16.05. | NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu | 902 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 16, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending March 31, 2025... ► Artikel lesen | |
| 15.05. | NANOVIRICIDES, INC. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 14.05. | NanoViricides: Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution | 895 | ACCESS Newswire | NanoViricides Explains Its Drug Strategy for Combating Viral Infections and Pandemics SHELTON, CT / ACCESS Newswire / May 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC)... ► Artikel lesen | |
| 08.05. | NanoViricides: Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo | 898 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 8, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company") today reported that it has received approval from the National Ethics Committee for Health (CNES)... ► Artikel lesen | |
| 05.05. | D.Boral Capital: NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC | 892 | Newsfile | Shelton, Connecticut--(Newsfile Corp. - May 5, 2025) - NanoViricides, Inc. (NYSE American: NNVC), (the "Company"), a leading clinical stage global pioneer in the development of broad-spectrum antivirals... ► Artikel lesen | |
| 29.04. | Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It | 761 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / April 29, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a leading global pioneer in the development of broad-spectrum antivirals... ► Artikel lesen | |
| 14.04. | Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak | 1.005 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / April 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a leading global pioneer in the development of broad-spectrum antivirals... ► Artikel lesen | |
| 11.03. | NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company | 1.206 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / March 11, 2025 / NanoViricides, Inc. (the "Company")(NYSE American:NNVC), a clinical-stage global leader developing revolutionary broad-spectrum antiviral drugs that... ► Artikel lesen |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 24,100 | +0,21 % | BERENBERG stuft Formycon auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Formycon von 32 auf 30 Euro gesenkt, aber die Einstufung auf "Buy" belassen. Die Mitte August veröffentlichten Quartalszahlen... ► Artikel lesen | |
| ONTO INNOVATION | 92,50 | -1,60 % | EQS-Media: LPKF Laser & Electronics SE: Onto Innovation und LPKF treiben gemeinsam die Massenproduktion von Glassubstraten für Halbleiter voran | EQS-Media / 02.04.2025 / 09:00 CET/CEST
Onto Innovation und LPKF treiben gemeinsam die Massenproduktion von Glassubstraten für Halbleiter voran
LPKF schließt sich dem Packaging Applications... ► Artikel lesen | |
| GAUZY | 5,310 | -2,92 % | Gauzy Ltd. Announces Second Quarter 2025 Results | Record Backlog Purchase Orders of $42.9 Million at Quarter End Highly Anticipated New Product Lines Announced; Includes Commercial Aircraft Cabin Shading, ADAS Smart Vision for Buses, and Pre-Fabricated... ► Artikel lesen | |
| GOMSPACE | 1,218 | +14,69 % | GomSpace Group AB: GomSpace Reports Strong Q2 Performance with Growth and Profitability | GomSpace releases Q2 2025 and half-year report, reporting strong year-on-year revenue growth and positive EBITDA and EBIT year-to-date.
SECOND QUARTER OF 2025
Order intake increased by 29% to 257... ► Artikel lesen | |
| KOPIN | 1,868 | -0,95 % | Kopin Corporation Announces Agreement for $15 Million Strategic Investment From Theon International Plc to Accelerate Global Defense Innovation | Kopin gains significant access to the European and NATO defense market
Accelerates development of critical technologies
Further strengthens Kopin's balance sheet
Fixed conversion... ► Artikel lesen | |
| VEECO INSTRUMENTS | 21,400 | 0,00 % | Veeco auf Oppenheimer-Konferenz: Strategischer Fokus auf Halbleiter | ||
| ZENTEK | 0,570 | +2,70 % | Zentek Ltd. - 6-K, Report of foreign issuer | ||
| SOLESENCE | 3,570 | +1,42 % | Solésence, Inc.: Solésence Reports Second Quarter 2025 Financial Results | ROMEOVILLE, Ill., July 31, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced... ► Artikel lesen | |
| DOTZ NANO | 0,019 | -5,00 % | XFRA 57N: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| OBDUCAT | 0,019 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 14.03.2025 | Das Instrument OBD SE0000514705 OBDUCAT AB B SK 8 EQUITY wird cum Kapitalmassnahme gehandelt am 14.03.2025 und ex Kapitalmassnahme am 17.03.2025 The instrument OBD SE0000514705 OBDUCAT AB B SK 8 EQUITY... ► Artikel lesen | |
| ACACIA RESEARCH | 2,760 | -1,43 % | Acacia Research und Partner entwickeln eine mit Bitcoin gesicherte Gewerbedarlehensstrategie | ||
| ADVANCE ZINCTEK | 0,665 | 0,00 % | ADVANCE ZINCTEK LIMITED: Response to ASX Price Query | ||
| LAMPETIA | 0,092 | 0,00 % | EQS-News: LEHNER INVESTMENTS AG: Jahresabschluss 2024 mit positivem Ergebnis | EQS-News: LEHNER INVESTMENTS AG
/ Schlagwort(e): Jahresergebnis
LEHNER INVESTMENTS AG: Jahresabschluss 2024 mit positivem Ergebnis
30.06.2025 / 16:18 CET/CEST
Für den... ► Artikel lesen | |
| NANOFOCUS | 1,240 | 0,00 % | NanoFocus: Hauptaktionär plant Squeeze-out | Die Carl Mahr Holding GmbH hat ein offizielles Verlangen auf Durchführung eines aktienrechtlichen Squeeze-outs bei der NanoFocus AG übermittelt. Demnach soll die Hauptversammlung einen Beschluss fassen... ► Artikel lesen | |
| RIBER | 3,135 | -2,49 % | RIBER receives an order for two production systems in Asia | Bezons (France), August 18, 2025 - 8:00 am - RIBER, a global market leader in molecular beam epitaxy (MBE) equipment for the semiconductor industry, announces the order of two new MBE 6000 production... ► Artikel lesen |
NANOVIRICIDES INC gehört der Branche Nanotechnologie an. Der aktuelle Kurs liegt bei 1,150 Euro und damit -3,36 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOVIRICIDES INC finden Sie auf Wallstreet Online.